Mouse and human FcR effector functions

@article{Bruhns2015MouseAH,
  title={Mouse and human FcR effector functions},
  author={Pierre Bruhns and Friederike J{\"o}nsson},
  journal={Immunological Reviews},
  year={2015},
  volume={268}
}
Mouse and human FcRs have been a major focus of attention not only of the scientific community, through the cloning and characterization of novel receptors, and of the medical community, through the identification of polymorphisms and linkage to disease but also of the pharmaceutical community, through the identification of FcRs as targets for therapy or engineering of Fc domains for the generation of enhanced therapeutic antibodies. The availability of knockout mouse lines for every single… 
Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species
TLDR
The results document the specific binding patterns for each of these IgG (sub)classes, reveal possible caveats of antibody‐based immunoassays, and will be a useful reference for the transition from one animal model to preclinical mouse models or human cell‐based bioassays.
Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic
TLDR
The genetic variants of FcRs are one of the key elements in the design of antibody therapeutics due to their variety of clinical outcomes among individuals and their influence on the susceptibility to infectious diseases or cancer in the perspective of F cRs-induced effector functions.
The high‐affinity receptor for IgG, FcγRI, of humans and non‐human primates
TLDR
This review will focus on what is currently known of how FcγRI interacts with IgG, from mutation studies and recent crystallographic studies of human FcβRI, and how amino acid sequence differences in the macaque F cγRI may affect this interaction.
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
TLDR
It is of major importance to consider FcγR-mediated effector functions for the efficacy of therapeutic mAbs as well as point mutations, altered glycosylation patterns, combination of different Fc subclasses, and Fc-truncation of the mAb.
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
TLDR
The underpinning structure-function relationships and how the Fc has been engineered to produce an increasing number of antibodies that are appearing in the clinic with augmented abilities to treat cancer are revealed.
In vivo effector functions of high-affinity mouse IgG receptor FcγRI in disease and therapy models.
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
TLDR
The genetic engineering approaches that have allowed isotype switching and Fc modifications to modulate effector functions and bioavailability (half-life), which together with the technologies for engineering the Fv fragment have been pivotal in generating more efficacious and better tolerated therapeutic antibodies to treat cancer.
Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors
TLDR
The design of a potent trivalent immunoglobulin G–Fc molecule that broadly inhibited IC-driven processes in a variety of immune cells expressing FcγRs was directed, and was highly efficacious in three different animal models of autoimmune diseases.
Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice
TLDR
It is shown that afucosylated human IgG1 also have enhanced effector functions against peritoneal metastasis of melanoma cells in mice through the evolutionary related mouse FcγRIV, indicating that this glycan change is functionally conserved between the species.
Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
TLDR
This review touches on recent aspects of FcγR and IgG immunobiology and its relationship with the present and future actions of therapeutic mAbs.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 354 REFERENCES
Properties of mouse and human IgG receptors and their contribution to disease models.
TLDR
These studies led to the identification of specific cell populations responsible for the induction of various inflammatory diseases and have revealed, in particular, the unexpected contribution of neutrophils and monocytes to the induction of anaphylactic shock.
Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn
TLDR
A consensus peptide sequence is discovered that binds to hFcRn and inhibits the binding of human IgG (hIgG) in vitro and represents a previously uncharacterized family of potential therapeutic agents for the treatment of humorally mediated autoimmune and other diseases.
Mouse model recapitulating human Fcγ receptor structural and functional diversity
TLDR
These human FcγRs are shown to function to mediate the immunomodulatory, inflammatory, and cytotoxic activities of human IgG antibody and Fc engineered variants and provide a platform for the detailed mechanistic analysis of therapeutic and pathogenic IgG antibodies.
Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B)
TLDR
Following an extensive immunisation protocol using FcγRIIB−/− mice, three unique mAb reagents are produced that are suitable for this purpose and demonstrate that they fall into two distinct categories; those which cause phosphorylation and subsequent activation of F cγR IIB (agonistic) and those that block receptor phosphorylated (antagonistic).
Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies
TLDR
The human FcγR-transgenic mice that have been used to study the role of these receptors in autoimmune, inflammatory, and allergic disease models are described.
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1
TLDR
It is proposed that higher affinity to FcRn at pH 7.4 adversely affects release into the serum and offsets the benefit of the enhanced binding at pH 6.0.
Unique Monoclonal Antibodies Define Expression of FcγRI on Macrophages and Mast Cell Lines and Demonstrate Heterogeneity Among Subcutaneous and Other Dendritic Cells 1
TLDR
In addition to any role in effector functions, FcγRI on APC may act as a link between innate and adaptive immunities by binding and mediating the uptake of T-independent immune complexes for presentation, thereby assisting in the development ofT-dependent immune responses.
Immunotherapy Targeting Inhibitory Fcγ Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization
TLDR
It is observed that the anti-FcγRIIB mAbs are rapidly and extensively consumed in vivo, both by the tumor and host cells, including B cells, leading to a precipitous loss from the circulation, likely explaining their suboptimal efficacy.
Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities
TLDR
The aim is to engineer non‐destructive human IgG constant regions for therapeutic applications where depletion of cells bearing the target antigen is undesirable and a lack of killing via Fcγ receptors (R) and complement but retention of neonatal FcR binding to maintain placental transport and the prolonged half‐life of IgG.
Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.
TLDR
It is determined that Fc domain variants that were capable of selectively engaging activating FcγRs substantially enhanced the in vitro and in vivo activity of anthrax toxin-neutralizing antibodies.
...
1
2
3
4
5
...